Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01Business Wire • 11/10/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSINewsfile Corp • 10/20/21
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure HoustonBusiness Wire • 09/28/21
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/13/21
Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual ConferenceBusiness Wire • 09/07/21
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer RecurrenceBenzinga • 06/07/21
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well ToleratedBusiness Wire • 06/07/21
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?The Motley Fool • 04/21/21
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on CommercializationBusiness Wire • 04/19/21
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual MeetingBusiness Wire • 04/14/21
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast CancerBusiness Wire • 04/12/21
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast CancerBusiness Wire • 04/10/21
Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-upBenzinga • 04/09/21
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-upBusiness Wire • 04/09/21
